PetMed Express ($PETS) CEO Menderes Akdag raised a few eyebrows on October 20 when he blamed his company's missed quarterly profit and sales targets on the weather. Specifically, he said in a conference call with investors, last winter's frigid temperatures shortened flea-and-tick season, which dampened demand for topical remedies. But an analyst interviewed by MarketWatch suspects the real culprit is that over-the-counter flea-and-tick fighters are losing ground to new pills like Nexgard, made by Frontline Vet Labs, and Merck ($MRK) Animal Health's Bravecto. PetMed's stock dropped 4% after it announced the missed quarterly results last Monday. Article